Home/Pipeline/LAG525 (ieramilimab)

LAG525 (ieramilimab)

Various Solid Tumors

Phase IIOut-licensed to Novartis

Key Facts

Indication

Various Solid Tumors

Phase

Phase II

Status

Out-licensed to Novartis

Company

Immutep

About Immutep

Immutep is a global leader in the development of immunotherapies targeting the LAG-3 immune checkpoint, with a mission to deliver safe and effective treatments for cancer and autoimmune diseases. The company's strategy is built on a multi-modal LAG-3 platform, featuring its lead clinical asset eftilagimod alfa (efti), a first-in-class MHC Class II agonist, and several other clinical-stage candidates. With strategic partnerships with major pharmaceutical companies and a pipeline advancing in key oncology indications, Immutep is positioned to capitalize on the growing immuno-oncology market.

View full company profile

Therapeutic Areas

Oncology Autoimmune Diseases

Other Various Solid Tumors Drugs

Drug	Company	Phase	Status
NUC-8232	NuCana	Phase 1	Active
TCR Library Program	Medigene	Discovery	Active
Guardant Infinity Biomarker Discovery	Guardant Health	Development/Commercial	Active
Cytotoxic Oncology Generic	MSN Laboratories	Pre‑clinical	Active
APCEDEN®	APAC Biotech	Approved	Commercial
Solid Tumor Profiling	Diatech Pharmacogenetics	Commercial	Active
BAVENCIO (avelumab)	EMD Serono	Approved	Active (Lifecycle Management)
FoundationOne®CDx Indication Expansion	Foundation Medicine	Approved/Commercial	Active
FoundationOne®Liquid CDx Indication Expansion	Foundation Medicine	Approved/Commercial	Active
177Lu‑BetaBart (RV‑01)	AtomVie Global Radiopharma	Phase 1/2a	Active
BeiGene Oncology Portfolio	EVA Pharma	Phase 2/3	Active
Bevacizumab Biosimilar	Bio Usawa Biotechnology	Preclinical	Active